LGH447 + LGH447 + midostaurin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
AML and High Risk MDS
Conditions
AML and High Risk MDS
Trial Timeline
Mar 20, 2014 → Apr 18, 2019
NCT ID
NCT02078609About LGH447 + LGH447 + midostaurin
LGH447 + LGH447 + midostaurin is a phase 1 stage product being developed by Novartis for AML and High Risk MDS. The current trial status is completed. This product is registered under clinical trial identifier NCT02078609. Target conditions include AML and High Risk MDS.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02078609 | Phase 1 | Completed |
Competing Products
20 competing products in AML and High Risk MDS